| Autor: |
Ross AM; Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.; BioScience and BioEngineering Research (BioSciBer), Bernal BioMaterials Cluster, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland., Leahy CI; Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.; BioScience and BioEngineering Research (BioSciBer), Bernal BioMaterials Cluster, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland., Neylon F; Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.; BioScience and BioEngineering Research (BioSciBer), Bernal BioMaterials Cluster, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland., Steigerova J; Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic., Flodr P; Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic.; Department of Clinical and Molecular Pathology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic., Navratilova M; Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic.; Department of Clinical and Molecular Pathology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic., Urbankova H; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky Univesity and University Hospital Olomouc, 779 00 Olomouc, Czech Republic., Vrzalikova K; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK., Mundo L; Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.; Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy., Lazzi S; Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy., Leoncini L; Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy., Pugh M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK., Murray PG; Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.; Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic. |
| Abstrakt: |
Epstein-Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorders, and, most recently, diffuse large B-cell lymphoma (DLBCL). Understanding how EBV contributes to the development of these different types of B-cell lymphoma has not only provided fundamental insights into the underlying mechanisms of viral oncogenesis, but has also highlighted potential new therapeutic opportunities. In this review, we describe the effects of EBV infection in normal B-cells and we address the germinal centre model of infection and how this can lead to lymphoma in some instances. We then explore the recent reclassification of EBV+ DLBCL as an established entity in the WHO fifth edition and ICC 2022 classifications, emphasising the unique nature of this entity. To that end, we also explore the unique genetic background of this entity and briefly discuss the potential role of the tumour microenvironment in lymphomagenesis and disease progression. Despite the recent progress in elucidating the mechanisms of this malignancy, much work remains to be done to improve patient stratification, treatment strategies, and outcomes. |
